News Bayer files 'safer, greener' MRI contrast agent in US FDA starts its review of Bayer's gadoquatrane, an MRI contrast agent that reduces the amount of gadolinium in medical imaging procedures.
News Bayer reveals phase 3 data for improved MRI contrast agent Bayer is close to filing a new MRI contrast agent that can reduce levels of gadolinium, which can have health and environmental consequences.
News BioMarin ends year with $4.8bn play for Amicus BioMarin takes a leap towards its $4bn revenue target with a $4.8bn deal to acquire Amicus, which has two rare disease therapies on the market.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.